Systemic Vasculitis: Clinical Trials

8 trials for Systemic Vasculitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed. 8 Not applicable.

By phase and status

PhaseTrialsStatus
Not applicable8Completed 8

Follow Systemic Vasculitis: new trials by email Literature Review of Systemic Vasculitis trials Research Report on Systemic Vasculitis

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis
vitamin D - ANCA-associated Vasculitis, Granulomatosis With Polyangiitis
Not applicableCompletedChristian Pagnoux1022020-08-012023-03-14
Effect of Tofacitinib in Treating ANCA-associated Vasculitis
Tofacitinib - ANCA Associated Vasculitis, Drug Use
Not applicableCompletedShanghai Zhongshan Hospital102019-12-012021-07-22
Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis
blood sample, urine sample - ANCA Associated Vasculitis
Not applicableCompletedUniversity Hospital, Bordeaux482018-12-142026-08-17
Aerobic Capacity and Strength Exercise in Takayasu's Arteritis
Combined acute physical exercises (strength and aerobic) - Physical Activity, Takayasu Arteritis
Not applicableCompletedUniversity of Sao Paulo122018-10-012021-04-30
Yellow Fever Vaccine in Patients With Rheumatic Diseases
Yellow Fever vaccine (17D) - Systemic Lupus, Rheumatoid Arthritis
Not applicableCompletedUniversity of Sao Paulo General Hospital6002018-01-312019-04-26
Magnetic Resonance Angiography vs Ultrasonography in Systemic Large vEssel vasculitiS
Ultrasound, MRA - Systemic Vasculitis
Not applicableCompletedHospital of Southern Norway Trust392013-12-012016-02-23
Study of One Protein Implicated in Wegener Disease
Physiopathology Endpoint Classification - Wegener's Granulomatosis
Not applicableCompletedAssistance Publique - Hôpitaux de Paris1382010-05-012026-03-31
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
Infliximab, Rituximab - Wegener's Granulomatosis, Churg-Strauss Syndrome
Not applicableCompletedAssistance Publique - Hôpitaux de Paris202004-05-012007-11-19

Narrower conditions

Granulomatosis with Polyangiitis (5)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3)  ·  Churg-Strauss Syndrome (3)  ·  Microscopic Polyangiitis (3)  ·  Takayasu Arteritis (3)  ·  Rheumatic Diseases (2)  ·  Arthritis, Juvenile (1)  ·  Arthritis, Rheumatoid (1)  ·  Dermatomyositis (1)  ·  Giant Cell Arteritis (1)  ·  Mixed Connective Tissue Disease (1)  ·  Motor Activity (1)  ·  Myositis (1)  ·  Recurrence (1)

Broader conditions

Cardiovascular Diseases (8)  ·  Skin Diseases (8)  ·  Skin Diseases, Vascular (8)  ·  Skin and Connective Tissue Diseases (8)  ·  Vascular Diseases (8)  ·  Autoimmune Diseases (7)  ·  Immune System Diseases (7)  ·  Vasculitis (7)  ·  Lung Diseases (5)  ·  Lung Diseases, Interstitial (5)  ·  Nervous System Diseases (5)  ·  Respiratory Tract Diseases (5)  ·  Brain Diseases (4)  ·  Central Nervous System Diseases (4)

Interventions

Blood Specimen Collection (1)  ·  Infliximab (1)  ·  Rituximab (1)  ·  Ultrasonography (1)  ·  Vitamin D (1)  ·  Yellow Fever Vaccine (1)  ·  tofacitinib (1)

Sponsors

Assistance Publique - Hôpitaux de Paris (2)  ·  Christian Pagnoux (1)  ·  Hospital of Southern Norway Trust (1)  ·  Shanghai Zhongshan Hospital (1)  ·  University Hospital, Bordeaux (1)  ·  University of Sao Paulo (1)  ·  University of Sao Paulo General Hospital (1)

Countries

France (3)  ·  Brazil (2)  ·  Canada (1)  ·  China (1)  ·  Norway (1)

Top investigators

Andreas Diamantopoulos, MD (1)  ·  Christian Pagnoux, MD (1)  ·  Eloisa Bonfa, MD, PhD (1)  ·  Lindi Jiang, PhD (1)  ·  Mathilde De Menthon,, MD, PhD (1)  ·  Samuel K Shinjo (1)

Results publications

PMID 34843469, PMID 42321206